DPYSL2 and diabetes mellitus: Our most recent report disclosed that hyperglycemia suppresses CRMP2 expression/activity and augments colorectal cancer (CRC) malignant traits; thus, CRC patients with diabetic comorbidity (CRC-DM) have significantly lower CRMP2 levels than CRC subjects and manifest advanced tumor stage [8].